Novel treatments for systemic lupus erythematosus

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 5, 2011, Pages 255-266

  Xiong, Wen ^a   Lahita, Robert G ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

anticytokine therapies; B cells; biologics; lupus; systemic lupus erythematosus

Indexed keywords

ABATACEPT; AIN 457; ALPHA INTERFERON; AMG 811; ATACICEPT; AZATHIOPRINE; BELIMUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE ANTIBODY; EPRATUZUMAB; ETANERCEPT; INDUCIBLE T CELL COSTIMULATOR LIGAND; INFLIXIMAB; INTERFERON ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 6; IXEKIZUMAB; JANUS KINASE 3; METHOTREXATE; MONOCLONAL ANTIBODY; OCRELIZUMAB; PLACEBO; RAPAMYCIN; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CLINICAL EVALUATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; GLOMERULONEPHRITIS; HUMAN; IMMUNOTHERAPY; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; LEGIONNAIRE DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; LYMPHOMA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; URINARY TRACT INFECTION; UVEITIS;

EID: 84857469048     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11415456     Document Type: Review

References (76)

1. Al-Mutairi S. Al-Awadhi A. Raghupathy R. Al-Khawari H. Sada P. Al-Herz A. et al (2007) Lupus patients with pulmonary involvement have a proinflammatory cytokines profile. Rheumatol Int 27: 621–630.
2. Anolik J. (2011) Immunologic reconstitution after rituximab in systemic lupus erythematosus: why should we care? J Rheumatol 38: 587–589.
3. Aringer M. Graninger W.B. Steiner G. Smolen J.S. (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50: 3161–3169.
4. Aringer M. Houssiau F. Gordon C. Graninger W.B. Voll R.E. Rath E. et al (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48: 1451–1454.
5. Aringer M. Smolen J.S. (2005) Cytokine expression in lupus kidneys. Lupus 14: 189–191.
6. Aringer M. Steiner G. Graninger W.B. Höfler E. Steiner C.W. Smolen J.S. (2007) Effect of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56: 274–279.
7. Bahjat F.R. Pine P.R. Reitsma A. Cassafer G. Baluom M. Grillo S. et al (2008) An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58: 1433–1444.
8. Bengtsson A. Sturfelt G. Truedsson L. Blomberg J. Alm G. Vallin H. et al (2000) Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664–671.
9. Bongartz T. Sutton A.J. Sweeting M.J. Buchan I. Matteson E.L. Montori V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 295: 2275–2285. Erratum J AM Med Assoc 295: 2482.
10. Bongu A. Chang E. Ramsey-Goldman R. (2002) Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol 16: 313–332.
11. Boumpas D.T. Furie R. Manzi S. Illei G.G. Wallace D.J. Balow J.E. et al (2003) A short course of BG 9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48: 719–727.
12. Brennan D. Yui M. Wuthrich R. Kelley V. (1989) Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 143: 3470–3475.
13. Bussel J.B. Schindler A.M. Grossbard E.B. (2007) R935788: a phase II, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult immune thrombocytopenic purpura (ITP) [abstract]. Blood 110: 1310–1310.
14. Calero I. Sanz I. (2010) Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med 10: 416–424.
15. Chen J. Fang Y. (2002) A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 64: 1071–1077.
16. Chun H.Y. Chung J.W. Kim H.A. Yun J.M. Jeon J.Y. Ye Y.M. et al (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27: 461–466.
17. Conti F. Ceccarelli F. Perricone C. Alessandri C. Conti V. Massaro L. et al (2011) Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford) [ePub ahead of print].
18. Deng G. Liu L. Bahjat F.R. Pine P.R. Tsokos G.C. (2010) Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 62: 2086–2092.
19. Dixon W.G. Watson K. Lunt M. Hyrich K.L. Silman A.J. Symmons D.P. (2006) British Society for Rheumatology Biologics Register Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: result from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2368–2376.
20. Dong G. Ye R. Shi W. Liu S. Wang T. Yang X. et al (2003) IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J 116: 543–548.
21. Edwards C.K. Zhou T. Zhang J. Baker T.J. De M. Long R.E. et al (1996) Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-a. J Immunol 157: 1758–1772.
22. Fairhurst A.M. Mathian A. Connolly J.E. Wang A. Gray H.F. George T.A. et al (2008) Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 38: 1948–1960.
23. Fernandez D. Bonilla E. Mirza N. Niland B. Perlet A. (2006) Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2983–2988.
24. Furie, R., Looney, R.J., Rovin, B., Latinis, Kevin M., Appel, G., Sanchez-Guerrero, J., et al. (2009) Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 60(suppl 1): S429. Abstract 1149.
25. Genovese M.C. Van den Bosch F. Roberson S.A. Bojin S. Biagini I.M. Ryan P. et al (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62: 929–939.
26. Haas C. Ryffel B. Le Hir M. (1998) IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 160: 3713–3718.
27. Hahn B.H. (2011) Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis 70(Suppl. 1): i64–i66.
28. Harigai M. Kawamoto M. Hara M. Kubota T. Kamatani N. Miyasaka N. (2008) Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 181: 2211–2219.
29. Houssiau F.A. Lefebvre C. Vanden Berghe M. Lambert M. Devogelaer J.P. Renauld J.C. (1995) Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393–395.
30. Hueber W. Patel D.D. Dryja T. Wright A.M. Koroleva I. Bruin G. et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 6(2, 52): 52–72.
31. Illei G.G. Shirota Y. Yarboro C.H. Daruwalla J. Tackey E. Takada K. et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62: 542–552.
32. Ishida H. Muchamuel T. Sakaguchi S. Andrade S. Menon S. Howard M. (1994) Continuous administration of anti-interleukin 10 antibody delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179: 305–310.
33. Iwai H. Abe M. Hirose S. Tsushima F. Tezuka K. Akiba H. et al (2003) Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 171: 2848–2854.
34. Jacobi A.M. Odendahl M. Reiter K. Bruns A. Burmester G.R. Radbruch A. et al (2003) Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48: 1332–1342.
35. Kalunian K.C. Davis J.C. Merrill J.T. Totoritis M.C. Wofsy D. (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 3251–3258.
36. Kawamoto M. Harigai M. Masako Hara M. Kawaguchi Y. Tezuka K. Tanaka M. et al (2006) Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-γ and anti-double-stranded DNA antibody production. Arthritis Res Ther 8: R62–R62.
37. Kawamura M. McVicar D.W. Johnston J.A. Blake T.B. Chen Y.Q. Lal B.K. et al (1994) Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 91: 6374–6378.
38. Kremer J.M. Bloom B.J. Breedveld F.C. Coombs J.H. Fletcher M.P. Gruben D. et al (2009) The Safety and Efficacy of a JAK Inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895–1905.
39. Kremer J.M. Westhovens R. Leon M. Di Giorgio E. Alten R. Steinfeld S. et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907–1915.
40. Krishnan S. Juang Y.T. Chowdhury B. Magilavy A. Fisher C.U. Nguyen H. et al (2008) Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 181: 8145–8152.
41. La Cava A. (2010) Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther 10: 1555–1561.
42. Lawson B.R. Prud'homme G.J. Chang Y. Gardner H.A. Kuan J. Kono D.H. et al (2000) Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J Clin Invest 106: 207–215.
43. Leombruno J.P. Einarson T.R. Keystone E.C. (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68: 1136–1145.
44. Liang B. Gardner D.B. Griswold D.E. Bugelski P.J. Song X.Y. (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119: 296–305.
45. Llorente L. Richaud-Patin Y. Garcia-Padilla C. Claret E. Jakez-Ocampo J. Cardiel M.H. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790–1800.
46. Matsumura R. Umemiya K. Sugiyama T. Sueishi M. Umibe T. Ichikawa K. et al (2009) Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 27: 416–421.
47. McAdam A.J. Chang T.T. Lumelsky A.E. Greenfield E.A. Boussiotis V.A. Duke-Cohan J.S. et al (2000) Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 165: 5035–5040.
48. Merrill J.T. Buyon J.P. Furie R.A. Latinis K.M. Gordon C. Hsieh H.J. et al (2011) Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus [ePub ahead of print].
49. Mihara M. Tan I. Chuzhin Y. Reddy B. Budhai L. Holzer A. et al (2000) CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 106: 91–101.
50. Morrow T. (2011) FDA to act on benlysta, rare new drug for lupus. Manag Care 20: 43–44.
51. Nurieva R.I. Treuting P. Duong J. Flavell R.A. Dong C. (2003) Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 111: 701–706.
52. Ota M. Duong B.H. Torkamani A. Doyle C.M. Gavin A.L. Ota T. et al (2010) Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 185: 4128–4136.
53. Perl A. Fernandez D.R. Telarico T. Doherty E. Francis L. Phillips P.E. (2009) T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol 21: 454–464.
54. Rönnblom L. Alm G.V. Eloranta M.L. (2009) Type I interferon and lupus. Curr Opin Rheumatol 21: 471–477.
55. Rottman J.B. Smith T. Tonra J.R. Ganley K. Bloom T. Silva R. et al (2001) The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2: 605–611.
56. Ryffel B. Car B.D. Gunn H. Roman D. Hiestand P. Mihatsch M.J. (1994) Interleukin-6 exacerbates glomerulonephritis in (NZB NZW)F1 mice. Am J Pathol 144: 927–937.
57. Santiago-Raber M.L. Baccala R. Haraldsson K.M. Choubey D. Stewart T.A. Kono D.H. et al (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197: 777–788.
58. Soforo E. Baumgartner M. Francis L. Allam F. Phillips P.E. Perl A. (2010) Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 37: 204–220.
59. Straub R.H. Harle P. Yamana S. Matsuda T. Takasugi K. Kishimoto T. et al (2006) Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54: 1778–1785.
60. Suzuki H. Yasukawa K. Saito T. Narazaki M. Hasegawa A. Taga T. et al (1993) Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 23: 1078–1082.
61. Theofilopoulos A.N. Lawson B.R. (1999) Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 58(Suppl. 1): I49–I55.
62. Tsai C.Y. Wu T.H. Yu C.L. Lu J.Y. Tsai Y.Y. (2000) Increased excretions of β-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm–Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207–214.
63. Uhm W.S. Na K. Song G.W. Jung S.S. Lee T. Park M.H. et al (2003) Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology 42: 935–938.
64. Uppal S.S. Hayat S.J. Raghupathy R. (2009) Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 18: 690–697.
65. Vadacca M. Margiotta D. Sambataro D. Buzzulini F. Lo Vullo M. Rigon A. et al (2010) BAFF/APRIL pathway in Sjögren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity. Reumatismo 62: 259–265.
66. Wallace D.J. Petri M. Olsen N. Kirou K. Dennis G. Yao Y. et al (2007) MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 56: S526–S527.
67. Wallace, D., Kalunian, K., Petri, M., Strand, V., Kilgallen, B., Barry, A., et al. (2010) Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus: results from EMBLEMTM, a phase IIb study. Ann Rheum Dis 69(suppl 3): 558. Abstract SAT0212.
68. Wang X. Huang W. Schiffer L.E. Mihara M. Akkerman A. Hiromatsu K. et al (2003) Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48: 495–506.
69. Weinblatt M.E. Kavanaugh A. Burgos-Vargas R. Dikranian A.H. Medrano-Ramirez G. Morales-Torres J.L. et al (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309–3318.
70. Wiglesworth A.K. Ennis K.M. Kockler D.R. (2010) Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus. Ann Pharmacother 44: 1955–1961.
71. Wiley R.E. Goncharova S. Shea T. Johnson J.R. Coyle A.J. Jordana M. (2003) Evaluation of inducible costimulator/B7-related protein-1 as a therapeutic target in a murine model of allergic airway inflammation. Am J Respir Cell Mol Biol 28: 722–730.
72. Wong C.K. Lit L.C. Tam L.S. Li E.K. Wong P.T. Lam C.W. (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127: 385–393.
73. Yao Y. Richman L. Higgs B.W. Morehouse C.A. de los Reyes M. Brohawn P. et al (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an antiinterferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60: 1785–1796.
74. Yin Z. Bahtiyar G. Zhang N. Liu L. Zhu P. Robertet M.E. et al (2002) IL-10 regulates murine lupus. J Immunol 169: 2148–2155.
75. Yoo D.-H. (2010) Anticytokine therapy in systemic lupus erythematosus. Lupus 19: 1460–1467.
76. Yoshinaga S.K. Zhang M. Pistillo J. Horan T. Khare S.D. Miner K. et al (2000) Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 12: 1439–1447.